CD7 false-positive acute myelogenous leukemia and promyelocytic leukemia cell line HL-60: Characterization of CD7 epitopes by four monoclonal antibodies
Article first published online: 11 JUL 2006
Copyright © 1991 Wiley-Liss, Inc., A Wiley Company
American Journal of Hematology
Volume 38, Issue 1, pages 72–74, September 1991
How to Cite
Imamura, N., Ota, H. and Kuramoto, A. (1991), CD7 false-positive acute myelogenous leukemia and promyelocytic leukemia cell line HL-60: Characterization of CD7 epitopes by four monoclonal antibodies. Am. J. Hematol., 38: 72–74. doi: 10.1002/ajh.2830380114
- Issue published online: 11 JUL 2006
- Article first published online: 11 JUL 2006
- Manuscript Accepted: 14 MAR 1991
- Manuscript Received: 8 MAR 1991
- flow cytometric analysis;
- IgG Fc receptor;
- HL-60 cell line
Phenotypes of cells from 12 patients with acute myelogenous leukemia (AML) were analysed by means of a fluorescence-activated cell sorter utilizing a panel of monoclonal antibodies (MAbs). A majority of the cells from peripheral blood coexpressed the antigens against MAbs CD11, CD13, and CD33 but did not express the antigens against CD1, CD3, CD4, CD5, CDB, CD19, CD20, CD21, CD41 and 42, and glycophorin A. Three out of the 12 cases expressed CD7 antigen. However, one of them showed no reaction with Tp40 MAb, whereas the others showed reaction with Leu9 and T55. The discrepancy of reactivities between Leu9 and Tp40 MAbs prompted us to study the promyelocytic leukemia cell line HL-60, which showed similar reactions against Leu9 and Tp40 MAbs. Leu9, OKT16, and T55 MAbs reacted strongly with HL60 cells, whereas Tp40 MAb, which reacted strongly with T-cell leukemia cell line Jurkat, showed no reaction.
The reactivity of Leu9, OKT16, and T55 MAbs with HL-60 cells was completely inhibited after preincubation with aggregated human immunoglobulin G (AHIG), which clearly shows the existence of nonspecific binding between these 3 MAbs and HL-60 cells via FcγR.
On the basis of our experiments, we conclude that HL-60 cells bind nonspecifically with Leu9, OKT16, and T55 MAbs via FcRI, and this is suggestive that de novo AML cells probably behave in the same fashion. Hence, we recommend that the utilization of murine IgG2a and IgG3 MAbs should be avoided especially in cell surface analysis of myeloid leukemic cells.